global
coronaviru
diseas
pandem
highlight
inher
suscept
specif
agegroup
cardiovascular
comorbid
individu
age
infect
viral
load
import
year
older
notabl
increas
risk
addit
patient
obes
heart
failur
coronari
arteri
diseas
diabet
mellitu
hypertens
also
increas
risk
like
deterior
seriou
critic
condit
infect
yet
clear
diseas
predispos
patient
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
veteran
affair
offic
research
develop
award
number
content
sole
respons
author
necessarili
repres
offici
view
fund
agenc
disclosur
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
sever
respons
infect
letter
lend
insight
perspect
observ
mani
rais
potenti
issu
use
angiotensin
convert
enzym
ace
inhibitor
acei
angiotensin
receptor
blocker
arb
may
lead
higher
suscept
infect
due
abil
increas
angiotensin
convert
enzym
mrna
express
howev
other
suggest
acei
arb
use
may
protect
understand
conflict
theori
import
recogn
play
multipl
role
context
princip
receptor
viru
entri
cell
highli
express
vascular
tissu
well
heart
lung
use
sarscov
receptor
entri
serin
proteas
protein
prime
interest
drug
target
camostat
start
attract
interest
though
rigor
evalu
use
remain
done
fulli
know
mechan
involv
viral
entri
viru
concentr
across
tissu
cell
type
distribut
viral
infect
within
cardiovascular
system
remain
specul
addit
neg
regul
angiotensin
ii
cleav
anim
model
studi
genet
modifi
mice
show
angiotensin
type
receptor
level
play
role
pathogenesi
acut
respiratori
distress
syndrom
ard
serv
protect
effect
reason
consequ
inhibit
ace
eg
aceiarb
within
context
mechanist
convolut
use
acei
arb
increas
gene
express
cardiac
cell
rat
model
respect
time
human
studi
show
signific
chang
plasma
activ
medic
presenc
type
heart
diseas
matter
whether
someon
take
acei
arb
determin
angiotensin
ii
level
plasma
activ
addit
studi
need
determin
variat
find
relat
differ
medic
cell
use
experi
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
express
increas
drug
rais
question
increas
infect
rapid
clinic
progress
patient
aceiarb
current
pauciti
clinic
data
support
hypothesi
increas
suscept
infect
patient
acei
arb
may
actual
confer
benefit
later
immunolog
respons
infect
mechan
action
propos
limit
excess
angiotensin
ii
bind
receptor
fulmin
viral
inflamm
excess
angiotensin
ii
bind
receptor
result
increas
vascular
permeabl
lung
propos
mechan
ard
similar
present
induc
lung
injuri
import
one
consid
bind
receptor
result
inactiv
downregul
increas
level
angiotensin
could
promot
cellular
injuri
lung
lead
pulmonari
edema
ard
support
hypothesi
recombin
human
insert
mice
defici
led
lower
risk
develop
ard
anim
expos
acidinduc
lung
injuri
thu
patient
administr
agent
specif
block
viru
bind
yet
affect
function
could
neutral
viru
might
net
effect
decreas
infect
maintain
angiotensin
ii
convers
potenti
mitig
lung
inflamm
damag
myocardi
injuri
associ
common
condit
patient
diagnos
wuhan
associ
higher
risk
inhospit
mortal
us
earli
unpublish
report
elev
troponin
bradycardia
sudden
cardiac
death
patient
also
earli
verbal
report
secondari
septiclik
cardiomyopathi
cardiogen
shock
develop
rather
late
usual
pre
might
hypothet
argument
discontinu
acei
arb
prior
infect
avoid
earli
excess
gene
upregul
ie
increas
potenti
viral
suscept
administr
acei
arb
could
mitig
impact
cellular
injuri
ard
infect
increas
pulmonari
vascular
permeabl
due
excess
impact
angiotensin
ii
dual
strategi
stop
aceiarb
earli
restart
later
patient
may
appear
reason
data
support
strategi
establish
dual
role
pathogen
expect
confound
impact
data
interpret
medic
clinic
outcom
furthermor
patient
guid
discontinu
medic
pandem
would
like
put
risk
decompens
heart
failur
uncontrol
hypertens
imper
decis
made
clinician
patient
ensur
risk
discontinu
drug
understood
weigh
uncertain
benefit
patient
cardiodepend
medic
prevail
approach
benefit
continu
outweigh
risk
focu
possibl
precaut
reduc
exposur
anoth
issu
pathogen
gener
immun
respons
appear
inappropri
case
lead
sever
immunopatholog
notabl
coronavirus
initi
robust
innat
immun
respons
caus
gener
inflamm
littl
specif
viru
inflammatori
respons
predominantli
mediat
cytokin
strategi
dampen
respons
challeng
due
lack
specif
inhibitor
adapt
immun
respons
viru
time
understood
specif
robust
helper
cell
respons
less
impress
antibodi
respons
asymptomat
mild
diseas
inde
limit
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
serolog
studi
report
one
patient
show
peak
specif
igm
day
diseas
onset
switch
igg
week
addit
combin
sera
patient
abl
neutral
vitro
plaqu
assay
suggest
possibl
mount
neutral
antibodi
respons
whether
kinet
titer
specif
antibodi
correl
diseas
sever
remain
investig
sinc
littl
known
pathogenesi
urgent
need
prospect
data
address
question
expediti
summar
tabl
number
gap
remain
fill
time
initi
highqual
cardiovascular
research
warrant
given
clear
scientif
aim
readili
avail
research
infrastructur
move
forward
widespread
use
import
drug
class
hypertens
cardiac
renal
diseas
manag
may
confound
interpret
impact
set
popul
studi
data
must
therefor
evalu
interpret
care
ultim
answer
question
promot
abil
mitig
global
impact
pandem
improv
individu
patient
outcom
critic
current
therapi
shown
effect
date
none
